Percutaneous Coronary Atherectomy DRG 318 Reimbursement Guide

DRG 318 covers percutaneous coronary atherectomy without placement of an intraluminal device, focusing on inpatient procedures to remove coronary plaque. This grouping matters for inpatient reimbursement because it sets the payment base for these cases and interacts with patient complexity and hospital adjustments under Medicare.

DRG 318 Overview

DRG 318 covers percutaneous coronary atherectomy procedures performed without placement of an intraluminal device, typically used to debulk atherosclerotic plaque in coronary arteries. This Diagnosis-Related Group applies to inpatient hospital stays where the primary procedure is atherectomy without stent or other intraluminal implant. It matters for Medicare payment because the grouping determines base reimbursement and influences adjustments for patient complexity and hospital characteristics. Hospitals and coders must accurately report the principal procedure and comorbid conditions to ensure correct Medicare inpatient payment.

Acute technical optimization studies examining procedural strategies and immediate safety outcomes for percutaneous coronary atherectomy without intraluminal device: these trials focus on procedural variables (e.g., atherectomy modality, lesion preparation techniques, adjunctive balloon angioplasty) in patients presenting with complex calcified coronary lesions who are candidates for atherectomy. They measure acute angiographic success, periprocedural myocardial injury, vascular complications, and short-term major adverse cardiac events to define best practices for device-less lesion debulking. Findings are directly relevant to clinicians performing the procedure and to payers because they inform resource use, length of stay, and complication rates that drive inpatient costs for this DRG.
Comparative effectiveness and real-world registry studies comparing atherectomy-based strategies versus alternative revascularization approaches in high-risk cohorts: these observational or pragmatic randomized studies enroll patients with heavily calcified or ostial coronary disease, many with comorbidities such as diabetes or chronic kidney disease, to compare outcomes of atherectomy without intraluminal scaffold versus other percutaneous strategies or surgical revascularization. Endpoints include freedom from repeat revascularization, device-related complications, renal injury, and cost-effectiveness over 6–12 months, providing actionable evidence on which subgroups derive the most benefit. Results help providers tailor revascularization decisions and help payers assess comparative value and appropriate utilization criteria for this DRG population.
Post-discharge functional outcomes and health economics studies assessing recovery, rehospitalization, and long-term resource utilization after atherectomy-only procedures: these cohort studies or secondary analyses of claims data follow patients discharged after the DRG 318 hospitalization to quantify rates of readmission, cardiac rehabilitation engagement, medication adherence, and quality-of-life trajectories over 1 year. By linking clinical outcomes with downstream costs and patterns of outpatient care, this research identifies drivers of preventable readmissions and opportunities for care coordination that can reduce total cost of care. Such evidence informs discharge planning, post-acute care pathways, and payer strategies to optimize value for patients treated under this DRG.

Acute technical optimization studies examining procedural strategies and immediate safety outcomes for percutaneous coronary atherectomy without intraluminal device: these trials focus on procedural variables (e.g., atherectomy modality, lesion preparation techniques, adjunctive balloon angioplasty) in patients presenting with complex calcified coronary lesions who are candidates for atherectomy. They measure acute angiographic success, periprocedural myocardial injury, vascular complications, and short-term major adverse cardiac events to define best practices for device-less lesion debulking. Findings are directly relevant to clinicians performing the procedure and to payers because they inform resource use, length of stay, and complication rates that drive inpatient costs for this DRG.
Comparative effectiveness and real-world registry studies comparing atherectomy-based strategies versus alternative revascularization approaches in high-risk cohorts: these observational or pragmatic randomized studies enroll patients with heavily calcified or ostial coronary disease, many with comorbidities such as diabetes or chronic kidney disease, to compare outcomes of atherectomy without intraluminal scaffold versus other percutaneous strategies or surgical revascularization. Endpoints include freedom from repeat revascularization, device-related complications, renal injury, and cost-effectiveness over 6–12 months, providing actionable evidence on which subgroups derive the most benefit. Results help providers tailor revascularization decisions and help payers assess comparative value and appropriate utilization criteria for this DRG population.
Post-discharge functional outcomes and health economics studies assessing recovery, rehospitalization, and long-term resource utilization after atherectomy-only procedures: these cohort studies or secondary analyses of claims data follow patients discharged after the DRG 318 hospitalization to quantify rates of readmission, cardiac rehabilitation engagement, medication adherence, and quality-of-life trajectories over 1 year. By linking clinical outcomes with downstream costs and patterns of outpatient care, this research identifies drivers of preventable readmissions and opportunities for care coordination that can reduce total cost of care. Such evidence informs discharge planning, post-acute care pathways, and payer strategies to optimize value for patients treated under this DRG.

OpenPayer

Summary & Overview

Percutaneous Coronary Atherectomy without Intraluminal Device: Inpatient Reimbursement Overview

DRG 318 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes